Teva Sues FDA Alleging Unlawful Interpretation of the Definition of “First Applicant”

October 24, 2018

USPTO Director Proposes New Patent Eligibility Guidance

October 15, 2018

Now Available! Seyfarth Shaw’s BioLoquitur Bulletin: Drugs Available in 2018 for Generic Competition

April 5, 2018

Good ANDA Submission Practices: Summary of Draft Guidance

April 2, 2018

Innovation in Hatch-Waxman and ANDA Litigation

March 12, 2018

Now Available! Seyfarth Shaw’s Hatch-Waxman and Biosimilars Litigation: 2017 Year-in-Review

February 8, 2018

2017 Patent Litigation: A Statistical Overview

January 17, 2018

FDA Releases Draft Guidance on Determining Whether to Submit an ANDA or a 505(b)(2) Application

December 4, 2017

Federal Circuit Confirms That It Is Bound By Congress And Supreme Court In Its Standard Of Review Of Appeals Under The AIA

May 3, 2016

Momenta v. Teva – Effective Claiming of Methods of Testing Drug Products

December 21, 2015